БЛОГ

Feb 17, 2021

Wall Street Looks Again at Bluebird, Rivals, After Gene-Therapy Setback

Posted by in category: biotech/medical

J.P. Morgan’s Cory Kasimov moved bluebird bio to Neutral from Overweight in response to news it is suspending trials of a treatment for sickle cell disease.

Leave a reply